Similar articles

• Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.

  Yu LT, Zhu J, Tan HQ, Wang GG, Teo KK, Liu LS. Yu LT, et al. Chin Med J (Engl). 2011 Jun;124(12):1763-8. Chin Med J (Engl). 2011. PMID: 21740829 Clinical Trial.
• Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).

  Cowan BR, Young AA, Anderson C, Doughty RN, Krittayaphong R, Lonn E, Marwick TH, Reid CM, Sanderson JE, Schmieder RE, Teo K, Wadham AK, Worthley SG, Yu CM, Yusuf S, Jennings GL; ONTARGET Investigators. Cowan BR, et al. Am J Cardiol. 2009 Dec 1;104(11):1484-9. doi: 10.1016/j.amjcard.2009.07.018. Epub 2009 Oct 14. Am J Cardiol. 2009. PMID: 19932779 Clinical Trial.
• The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.

  Unger T. Unger T. Am J Cardiol. 2003 May 22;91(10A):28G-34G. doi: 10.1016/s0002-9149(03)00230-3. Am J Cardiol. 2003. PMID: 12781906 Review.
• Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials.

  Böhm M, Baumhäkel M, Teo K, Sleight P, Probstfield J, Gao P, Mann JF, Diaz R, Dagenais GR, Jennings GL, Liu L, Jansky P, Yusuf S; ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators. Böhm M, et al. Circulation. 2010 Mar 30;121(12):1439-46. doi: 10.1161/CIRCULATIONAHA.109.864199. Epub 2010 Mar 15. Circulation. 2010. PMID: 20231536 Clinical Trial.
• Telmisartan prevents cardiovascular events in a broad group of at-risk patients.

  Baumhäkel M, Böhm M. Baumhäkel M, et al. Expert Opin Pharmacother. 2009 Dec;10(18):3113-7. doi: 10.1517/14656560903449231. Expert Opin Pharmacother. 2009. PMID: 19925045 Review.